Helix Biopharma (HBPCF)
(Delayed Data from OTC)
$0.17 USD
0.00 (0.00%)
Updated Jul 9, 2024 03:42 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Helix Biopharma Corp falls in the month of July.
All items in Millions except Per Share data.
7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | 7/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 3 | 3 | 3 | 0 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 3 | 3 | 3 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1 | 3 | 3 | 4 | 1 |
Liabilities & Shareholders Equity | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | 7/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 2 | 2 | 0 | 0 |
Accounts Payable | 1 | 0 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 1 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 1 | 3 | 3 | 1 | 3 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 1 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1 | 3 | 4 | 1 | 3 |
Shareholders Equity | 7/31/2023 | 7/31/2022 | 7/31/2021 | 7/31/2020 | 7/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 116 | 123 | 124 | 116 | 109 |
Capital Surplus | 33 | 30 | 22 | 19 | 18 |
Retained Earnings | -150 | -154 | -148 | -134 | -130 |
Other Equity | 1 | 2 | 1 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | -1 | 0 | -1 | 2 | -2 |
Total Liabilities & Shareholder's Equity | 1 | 3 | 3 | 4 | 1 |
Total Common Equity | -1 | 0 | -1 | 2 | -2 |
Shares Outstanding | 200.00 | 171.80 | 141.10 | 132.90 | 111.20 |
Book Value Per Share | 0.00 | 0.00 | -0.01 | 0.02 | -0.02 |
Fiscal Year End for Helix Biopharma Corp falls in the month of July.
All items in Millions except Per Share data.
4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 1 | 0 | 1 | 1 | 1 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 |
Total Current Assets | 1 | 0 | 1 | 1 | 1 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 1 | 0 | 1 | 1 | 1 |
Liabilities & Shareholders Equity | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 0 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 1 | 0 | 1 | 1 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 1 | 0 | 1 | 1 | 1 |
Shareholders Equity | 4/30/2024 | 1/31/2024 | 10/31/2023 | 7/31/2023 | 4/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 116 | 116 | 116 | 116 | 116 |
Capital Surplus | 34 | 34 | 33 | 33 | 31 |
Retained Earnings | -151 | -151 | -149 | -150 | -147 |
Other Equity | 1 | 1 | 1 | 1 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 0 | 0 | 0 | -1 | 1 |
Total Liabilities & Shareholder's Equity | 1 | 0 | 1 | 1 | 1 |
Total Common Equity | 0 | 0 | 0 | -1 | 1 |
Shares Outstanding | 229.40 | 216.60 | 216.60 | 200.00 | 200.00 |
Book Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |